BioCentury
ARTICLE | Clinical News

CHS-131: Phase IIb data

July 11, 2016 7:00 AM UTC

Top-line data from a double-blind Phase IIb trial in 227 treatment-naive patients with RRMS showed that once-daily 3 mg oral CHS-131 met the primary endpoint of reducing the cumulative number of total...